A novel inhibitor of p75-neurotrophin receptor improves functional outcomes in two models of traumatic brain injury. by Delbary-Gossart, Sandrine et al.
UCSF
UC San Francisco Previously Published Works
Title
A novel inhibitor of p75-neurotrophin receptor improves functional outcomes in two models 


















eScholarship.org Powered by the California Digital Library
University of California
A novel inhibitor of p75-neurotrophin receptor
improves functional outcomes in two models of
traumatic brain injury
Sandrine Delbary-Gossart,1, Sangmi Lee,2, Marco Baroni,3 Isabelle Lamarche,4
Michele Arnone,4 Benoit Canolle,4 Amity Lin,2 Jeffrey Sacramento,2 Ernesto A. Salegio,2
Marie-Noelle Castel,4 Nathalie Delesque-Touchard,4 Antoine Alam,4 Patricia Laboudie,4
Badia Ferzaz,4 Pierre Savi,4 Jean-Marc Herbert,4 Geoffrey T. Manley,2 Adam R. Ferguson,2
Jacqueline C. Bresnahan,2 Franc¸oise Bono1 and Michael S. Beattie2
These authors contributed equally to this work.
The p75 neurotrophin receptor is important in multiple physiological actions including neuronal survival and neurite outgrowth
during development, and after central nervous system injury. We have discovered a novel piperazine-derived compound, EVT901,
which interferes with p75 neurotrophin receptor oligomerization through direct interaction with the first cysteine-rich domain of
the extracellular region. Using ligand binding assays with cysteine-rich domains-fused p75 neurotrophin receptor, we confirmed
that EVT901 interferes with oligomerization of full-length p75 neurotrophin receptor in a dose-dependent manner. Here we report
that EVT901 reduces binding of pro-nerve growth factor to p75 neurotrophin receptor, blocks pro-nerve growth factor induced
apoptosis in cells expressing p75 neurotrophin receptor, and enhances neurite outgrowth in vitro. Furthermore, we demonstrate
that EVT901 abrogates p75 neurotrophin receptor signalling by other ligands, such as prion peptide and amyloid-b. To test the
efficacy of EVT901 in vivo, we evaluated the outcome in two models of traumatic brain injury. We generated controlled cortical
impacts in adult rats. Using unbiased stereological analysis, we found that EVT901 delivered intravenously daily for 1 week after
injury, reduced lesion size, protected cortical neurons and oligodendrocytes, and had a positive effect on neurological function.
After lateral fluid percussion injury in adult rats, oral treatment with EVT901 reduced neuronal death in the hippocampus and
thalamus, reduced long-term cognitive deficits, and reduced the occurrence of post-traumatic seizure activity. Together, these
studies provide a new reagent for altering p75 neurotrophin receptor actions after injury and suggest that EVT901 may be
useful in treatment of central nervous system trauma and other neurological disorders where p75 neurotrophin receptor signalling
is affected.
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Introduction
The p75 neurotrophin receptor (p75NTR, encoded by
NGFR) is a transmembrane glycoprotein member of the
TNF receptor (TNFR) superfamily, characterized by four
cysteine-rich domains (CRDs) in its extracellular region
(Underwood and Coulson, 2008). P75NTR binds to all
neurotrophins with similar affinity (109 M) to mediate
various functions (Hempstead, 2002). p75NTR as a mono-
mer can interact with tropomyosin receptor kinase (Trk;
TrkA, B and C, encoded by NTRK1, NTRK2 and
NTRK3, respectively) and potentiate Trk signalling, leading
to neuronal survival, neurite outgrowth, and axonal regen-
eration (Chan et al., 2000). However, p75NTR can also
mediate cell death through pro-apoptotic signalling in neu-
rons, oligodendrocytes and Schwann cells, linked to the
binding of pro-neurotrophins (pro-NGF, pro-BDNF)
(Chan et al., 2000; Beattie et al., 2002; Roux and Barker,
2002; Gentry et al., 2004; Underwood and Coulson, 2008).
Recent work has also shown that aggregated oligomers
(prion peptide fragment PrP, amyloid peptide) interact
with p75NTR leading to cell death in vitro (Dechant and
Barde, 2002; Hempstead, 2002; Roux and Barker, 2002;
Gentry et al., 2004), and that p75NTR oligomers cooperate
with many different protein partners (Nogo receptor,
LINGO1, sortilin) to form multimeric receptor complexes
leading to apoptosis and axonal outgrowth inhibition
(Nykjaer et al., 2005; Hempstead, 2006).
Many TNFR superfamily members exist as pre-assembled
oligomers on the cell surface before ligand binding, through
a specific self-association domain, the pre-ligand assembly
domain (PLAD; Chan et al., 2000). This amino acid se-
quence, located in the CRD1 of the receptor, mediates re-
ceptor assembly, allowing ligand binding and receptor
functioning (Chan, 2007). Such a domain has not yet
been identified for p75NTR.
Although p75NTR is mainly expressed as a 75 kDa
transmembrane glycoprotein, there is a protein isoform of
p75NTR (s-p75NTR) that arises from alternative splicing
of exon III and lacks the CRDs 2–4 (Roux and Barker,
2002). Soluble p75NTR (s-p75NTR) is critical for develop-
ment of both the nervous and vascular systems (von Schack
et al., 2001). Although s-p75NTR is unable to bind neuro-
trophins, cross-linked s-p75NTR might be activated
through the pre-ligand assembly domain (Della-Bianca et
al., 2001; Yaar et al., 2002).
P75NTR expression is limited in adulthood to some per-
ipheral tissues and a few brain regions (Schor, 2005).
However, injury-induced p75NTR expression has been re-
ported in vivo in various CNS pathologies (Beattie et al.,
2002; Dechant and Barde, 2002; Turner et al., 2004;
Diarra et al., 2009). Reduction of p75NTR activity can
protect cortical neurons from cell death after close axotomy
(Harrington et al., 2004), and a novel peptide antagonist of
the p75NTR protects oligodendrocytes after spinal cord
injury and promotes better neurological recovery (Tep et
al., 2013). Thus, p75NTR interactions with co-receptors
could provide a target for both neuroprotection and en-
hancement of axonal growth, if it were possible to reduce
p75NTR homodimerization or interactions with ‘negative’
co-receptors while simultaneously enhancing heterodimeri-
zation with TrkA. To that end, we attempted to find se-
lective inhibitors of p75NTR pre-ligand dimerization able
to block both s-p75NTR and p75NTR signalling, and to
modulate Trks/p75NTR signalling. Recently, we identified
EVT901 as such an antagonist of p75NTR, and here,
report that EVT901 inhibits p75NTR oligomerization in
vitro while increasing TrkA phosphorylation, blocks apop-
tosis and increases neurite outgrowth in neuroblastoma
cells. In cortical oligodendrocyte cultures, EVT901 reduced
p75NTR expression and cell death produced by proNGF.
In vivo, traumatic brain injury (TBI) increased the expres-
sion of both p75NTR and proNGF in both controlled cor-
tical impact (CCI-TBI) and fluid percussion injury (FPI-TBI)
models of TBI, and EVT901 showed neuroprotection in
both models, and reduced post-TBI seizure susceptibility.
Together, these results suggest the utility of targeting
p75NTR oligomerization in CNS trauma, and provide a




Adult male Long-Evans rats (225 g, Simonsen Laboratories)
were used for CCI-TBI study. All animal experiments were
approved by the Institutional Laboratory Animal Care and
Use Committee of University of California San Francisco and
performed in compliance with NIH guidelines. Adult male
Sprague Dawley rats (170–230 g, strain RjHan) were used
for the FPI-TBI study. All animal treatment procedures
described in this aspect of the study were approved by the
Animal Care and Use Committee of Sanofi. The animal facil-
ities are fully accredited by Association for Assessment and
Accreditation of Laboratory Animal Care International
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(AAALAC). Rats were housed individually and maintained on
a 12 h light/dark cycle with free access to food and water.
In vitro assays to examine EVT901
effects on p75NTR oligomerization
Human cell lines
Human Embryonic Kidney (HEK) 293T cells and human
neuroblastoma SHSY-5Y cells were from ATCC [authenticated
by the provider using short tandem repeat (STR) profiling].
Neuroblastoma SK-N-BE p75NTR (BEp75) cell line, stably
expressing the human full-length p75NTR, was kindly pro-
vided by Della Valle G (Department of Genetics and
Microbiology, University of Pavia, Italy), and the molecular
analyses have been previously described (Bunone et al.,
1997). All cell lines were maintained in appropriate media
supplemented with foetal calf serum and glutamine and were
tested for mycoplasma contamination.
Construction of p75NTR-tagged proteins
The human full-length p75NTR was reverse-transcribed and
amplified from SKNBE-p75NTR cells. The PCR product was
subcloned into the pDisplay vector to obtain the construct HA-
p75NTR or into pCMV-Tag4A to obtain Flag-p75NTR. The
CRD1p75NTR construct, inserted into the pDisplay vector,
contains sequences representing the first CRD (AA29-64) dir-
ectly linked to amino acid residues 214–427 of the receptor
p75NTR (deletion of CRD2–4). Chimera CRD1-CD40 is com-
posed of the first CRD of p75NTR (AA29-64, fragment 1)
linked to human CD40 receptor deleted in CRD1 (AA60-
277, fragment 2) inserted into the pDisplay vector. The
human CD40 full-length (AA1-277) was cloned into the pCI-
neo vector (Fig. 1E).
Concerning the AP-p75NTR construct, alkaline phosphatase
(AP) was fused to the NH2-terminus of the extracellular
domain of the receptor p75NTR (containing the CRDs 1–4)
and cloned into pcDNA-FRTV5His TOPO vector to obtain a
soluble form of p75NTR tagged with alkaline phosphatase. All
the resulting cDNAs for the different constructs were
sequenced to verify the correct reading frame.
Binding of soluble AP-p75NTR
Binding experiments were performed on SKNBE-p75NTR
using a soluble form of the receptor p75NTR fused to alkaline
phosphatase (AP-p75NTR) as ligand obtained after transient
transfection of HEK293T cells for 3 days. Briefly, SKNBE-
p75NTR cells (2.5  104 cells/well) were plated in 96-well
plates for 24 h, and preincubated (37 C) for 1 h with increas-
ing concentrations of EVT901 followed by addition of 10 nM
AP-p75NTR for 1 h. Cells were filtered (Skatron), separately
collected with addition of specific substrate (CDP star) for
measurement of alkaline phosphatase activity.
Binding of NGF
Binding of 125I-NGF (2000Ci/mM, Amersham) was carried
out on cell suspensions of SK-N-BE cells according to the
method described by Weskamp and Reichardt (1991). The
specific binding was defined as the difference between the
total binding and the non-specific binding [measured after
1 h of preincubation of the cells with unlabelled NGF
(1 mM)]. Competition experiments were done with 0.3 nM of
125I-NGF and preincubation with increasing doses of EVT901.
Oligomerization of tagged p75NTR
HEK293T cells (3  106 cells/flask) were transiently co-
transfected for 24 h with equal amount of DNA from the
p75NTR full-length tagged either in NH2-terminal with an
haemagglutinin A epitope tag (HA) (HA-p75NTR) or in C-
terminal with a Flag epitope tag (Flag-p75NTR), using the
FuGENE 6 reagent (Roche Applied System). After treatment
for 24 h with EVT901, cells were lysed and the supernatants
were collected. Equal amounts of proteins were dispatched
onto anti-flag M2 coated 96 well plates (Sigma-Aldrich) for
1 h at room temperature, followed by washing, incubation
with anti-HA horseradish peroxidase (HRP), and reaction
with specific substrate. Quantification was measured using a
microplate fluorometer and expressed as OD (450 nm reading).
Error bar indicates  standard error of the mean (SEM).
Induction of cell death
SH-SY5Y cells (1.5  106 cells/ml in 35-mm collagen-coated
dishes) were stimulated for 48 h with pro-NGF (10 ng/ml,
SCIL proteins), PrP106-126 (25 mM, Bachem), or amyloid-b1–40
(10 mM, Bachem) in presence or not of EVT901. Apoptosis
was evaluated with a photometric enzyme immunoassay (cell
death detection ELISA, Roche) for the quantitative detection of
cytoplasmic mono- and oligonucleosomes. Results are ex-
pressed as per cent of inhibition of apoptosis versus untreated.
For studies with HEK293T, cells were transiently transfected
with the same amount of DNA from different constructs:
empty vector (control), full-length of p75NTR (p75NTR),
short-form of p75NTR (CRD1-p75NTR), full-length of
CD40, or a chimera CD40-CRD1p75NTR, and for specificity
studies with FAS, TNFRI, TNFRII, HVEM, LTbR, 4.1BB, or
BCMA receptors. Then, cells were treated with EVT901
(100 nM) for 24 h, and apoptosis was measured and expressed
as mean number of oligonucleosomes/106 cells. Error bar
indicates  SEM.
Neuritogenesis of SH-SY5Y cells
SH-SY5Y cells (7.5  104 cells/well) were incubated in colla-
gen-coated 8-well plates overnight at 37 C, then treated in
serum-free medium, with either recombinant human NGF
(10 ng/ml, R&D systems) or different concentrations of
EVT901, and maintained in the same media for 3 days at
37 C. The neurite length were visualized after staining with
May-Grunwald-Giemsa and digitally photographed from ran-
domly selected image fields.
Quantification of TrkA phosphorylation
Confluent SH-SY5Y cells were serum-deprived, and treated
with NGF (10 ng/ml) or EVT901 (100 nM) for 1 to 3 days.
After cell lysis, equal amounts of total protein were used for
quantification of the levels of total TrkA or phosphorylated
TrkA (Tyr490) using specific sandwich ELISA kits (PathScan,
Cell Signaling). Results are expressed as OD450. Error bar
indicates SEM.
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Figure 1 Mechanism of action through the CRD1 domain of p75NTR: cellular response and induction of neuritogenesis. (A)
EVT901 inhibits the binding of AP-p75NTR to the receptor p75NTR. Binding experiments on SKN-BE-p75NTR with soluble AP-p75NTR (10 nM) in
the presence of increasing concentrations of EVT901. Data are reported as mean % inhibition of binding, representative of three independent
experiments. (B) Competition of 125I-NGF binding with EVT901. Binding of 125I-NGF (0.3 nM) to SKNBE-p75NTR in the presence of increasing
concentrations of EVT901. Results are mean % inhibition of specific binding, representative of three independent experiments. (C) HEK293T cells
transiently co-transfected with the same amount of DNA originating from the p75NTR full-length tagged either in C-terminal with HA (HA- p75NTR)
or in N-terminal with Flag (Flag-p75NTR) and then treated or not with the compound EVT901 at 100 nM for 24 h. Oligomerization evaluated using an
ELISA assay with flag-coated plates and anti-HA-HRP antibody [two-way ANOVA, EVT901 dose effect, F(4,94) = 46.85, P5 0.0001; Tag,
F(3,94) = 394.40, P5 0.0001; EVT901 dose  Tag, F(12,94) = 46.82, P5 0.0001]. P5 0.0001 compared to 0. Data are indicated as mean  SEM
from six independent experiments. (D and E) HEK293T cells transiently transfected for 2 days with the same amount of DNA originating from the
indicated constructs: empty vector (control), full-length of p75NTR (p75NTR), short-form of p75NTR (CRD1-p75NTR), full-length of CD40 (CD40),
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Primary oligodendrocyte cell culture
Primary oligodendrocyte cell culture was performed as
described previously (Miller et al., 2007; Veiga et al., 2011).
Briefly, postnatal Day 1–2 Sprague Dawley rat pups were
sacrificed by decapitation and the cerebral cortices were
removed and placed in the dissecting media with antibiotic/
antimitotic (Sigma) containing 7.1mg/ml NaCl2, 0.36mg/ml
KCl, 0.166mg/ml KH2PO4, 2.57mg/ml D-Glucose, 2.4mg/ml
NaHCO3, 0.01mg/ml phenol red, 0.9mg/ml bovine serum al-
bumin (BSA) Fraction V, and 0.33mg/ml MgSO4. The cortices
were minced by pipetting with a 10ml pipette plus trypsin
(10 trypsin solution, Sigma) and incubated for 20min at
37 C. Next, DNase (10 DNase, Sigma) and trypsin inhibitor
(10 trypsin inhibitor, Sigma) were added and pipetted with a
10ml pipette until the suspension was homogenous. The sus-
pension was filtered through 180mm nylon net filters
(Millipore) and then centrifuged at 2000 rpm for 5min. Cells
were resuspended in media [Dulbecco’s modified Eagle
medium (Gibco) including 10% foetal bovine serum, 292 mg/
ml L-glutamine (Sigma), 1mM sodium pyruvate (Invitrogen)
and 0.04mg/ml gentamicin (Invitrogen)], filtered through a cell
strainer (40 mm nylon mesh, Fisher), and then centrifuged at
300 relative centrifugal force (rcf) for 5min. Cells were resus-
pended in media. Cells were counted using a haemocytometer
and placed in T-75 flasks (1.5  107 cells/flask). Flasks were
kept in an incubator at 37 C/5% CO2. Media was replaced
after 24 h and every 3 days thereafter. Cells were allowed to
proliferate until confluent, corresponding to Day 10–14 post
plating cells. Cells were shaken on an orbital shaker at
200 rpm overnight. The floating cells were collected in the
50ml of falcon tube [split into two tubes for each oligodendro-
cyte precursor cell (OPC) and oligodendrocyte cells] and cen-
trifuged at 300 rcf for 5min. Cells were resuspended with 5ml
of either OPC media including PDGF and bFGF or oligo-
dendrocyte media including L-thyronine and L-thyroxine.
The resuspended cells were placed on 2.5mm petri dish and
incubated for 45min. Petri dishes were then gently rinsed with
media and filtered through the cell strainer (40 mm Nylon
Mesh, Fisher). Cells were incubated with anti-mouse IgG mag-
netic beads (Invitrogen) precoated with anti-CD11b Ab
(Serotec) for 30min at 4 C on a rocker. After washing
beads with washing buffer [0.1% BSA, 2mM EDTA, pH 7.4
in phosphate-buffered saline (PBS)], tubes were placed in a
magnet holster for 2min. The supernatant was transferred
into 50ml falcon tube. Cells were counted using a haemocyt-
ometer. Cells (2.5  105) were seeded into 48-well plates with
poly-D-lysine coated cover glass (BD Bioscience). No serum
was used during OPC/oligodendrocyte isolation to prevent
OPC differentiation to oligodendrocyte cells. Each OPC and
oligodendrocyte medium was replaced every day to maintain
OPCs and proliferate oligodendrocyte cells, respectively, for 3
days. On Day 3, cells were treated with proNGF or/and
EVT901.
Treatment with proNGF and EVT901
Studies were done to determine the optimal concentration of
proNGF to induce apoptotic cell death in OPC and oligo-
dendrocyte cultures: 0.5–100 ng/ml of proNGF (cleavage resist-
ant mutant mouse proNGF, Alamone) was added to the OPC
or oligodendrocyte media and incubated for 24 h. For reported
experiments, the negative control did not contain proNGF,
while the positive control contained 10 ng/ml of mature NGF
(mNGF) (Harlan), and this was added to the cells and incu-
bated for 24 h. For inhibition studies, 0, 1, 10, 30, 100, and
300 nM of EVT901 were added into the media. Mouse
proNGF (50 ng/ml) was added to induce apoptotic cell death
in OPC/oligodendrocyte cells and cells were kept for 24 h at
37 C in a 5% CO2 incubator. Sample size was determined
based on previous studies (Miller et al., 2007; Veiga et al.,
2011).
Figure 1 Continued
or a chimera of CD40 and the CRD1 domain of p75NTR (CD40-CRD1-p75NTR) (E), and then treated or not with the compound EVT901 at
100 nM for 24 h. Apoptosis quantified using an ELISA kit and data are expressed as mean number of oligonucleosomes/106 cells  SEM, three
independent experiments. Two-way ANOVA [EVT901 dose effect, F(1,68) = 53.2, P5 0.0001; constructs, F(4,68) = 20.77, P5 0.0001; EVT901
effect  constructs, F(4,68) = 12.32, P5 0.0001]. P5 0.005, P5 0.001 (EVT901 versus untreated), ###P5 0.001 (untreated control versus
untreated constructs). (F) HEK293T cells transiently transfected for 24 h with the indicated constructs: empty vector (control), full-length of
p75NTR (p75NTR), FAS, TNFRI, TNFRII, HVEM, LTbR, 4.1BB, or BCMA receptors, and then treated or not with the compound EVT901 at
100 nM for 24 h. Apoptosis was measured and expressed as mean number of oligonucleosomes/106 cells  SEM. Data are representative of two
independent experiments. Two-way ANOVA [EVT901 dose effect, F(3,134) = 8.75, P5 0.0001; constructs, F(8,134) = 28.34, P5 0.0001; EVT901
dose effects  constructs, F(6,134) = 6.75, P5 0.0001]. P5 0.001 (EVT901 versus untreated; ###P5 0.001 (untreated control versus un-
treated constructs). (G) Inhibition of specific p75NTR ligand-induced apoptosis. Subconfluent monolayers of SH-SY5Y cells stimulated for 48 h
with pro-NGF (10 ng/ml; solid blue line), PrP106–126 (10mM; solid black line), or amyloid-b1–40 (10mM; dashed black line), in addition to increasing
concentrations of EVT901 (from 0.01 to 100 nM). Apoptosis was measured and reported as % inhibition of apoptosis, representative of three
independent experiments. (H) Induction of neuritogenesis through TrkA phosphorylation. SHSY-5Y cells serum-deprived, and treated with rhNGF
(10 ng/ml) or EVT901 (0.01 to 10 nM), and then maintained in the same media for 3 days. The neurite length was visualized after staining with May-
Grunwald-Giemsa and digitally photographed from randomly selected image fields (magnification 10). (I) Confluent SHSY-5Y cells serum-
deprived, and treated with NGF (10 ng/ml) or EVT901 (100 nM) for different times (1–3 days). Quantification of levels of total TrkA or
phosphorylated TrkA (Tyr490) expressed as OD450 and representative of three independent experiments. Four-way ANOVA [time effect,
F(2,18) = 21.0, P5 0.001; NGF effect, F(1,18) = 152.75, P5 0.0001; EVT901 effect, F(1,18) = 4.32, P = 0.052; pTrkA, not significant]. Note that
there are significant interactions: time  NGF, F(2,18) = 33.81, P5 0.0001; time  EVT901, F(2,8) = 40.19, P5 0.0001; time  pTrkA,
F(2,18) = 5.99, P = 0.01; NGF  pTrkA, F(1,18) = 167.68, P = 0.0001; EVT901  pTrkA, F(1,18) = 43.79, P = 0.00010; time  NGF  pTrkA,
F(2,18) = 50.54, P = 0.0001; time  EVT901  pTrkA, F(2,18) = 25.23, P = 0.0001. P5 0.001 compared to untreated control. (J) Chemical
structure of EVT901; 1-(phenyl-3, 6-dihydro-2H-pyridinyl)-2-(aryl-bridged piperazines)-ethanone.
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Caspase activity assays
To detect apoptotic cell death, caspase activity was measured
using a pan-caspase apoptotic detection kit
(Carboxylflurorescein FLICA; Immunochemistry
Technologies, LLC) according to the manufacturer’s protocol.
Briefly, after treating cells with proNGF and EVT901 for 24 h,
cells were washed with PBS twice and then the 30 FLICA
solution was added to the medium at a 1:30 ratio. Cells were
incubated for 1 h at 37 C/5% CO2 incubator, and protected
from light. After washing cells twice with wash buffer, cells
were fixed with 4% paraformaldehyde for 20min. After wash-
ing with PBS, cells were mounted on slides containing a drop
of mounting media (ProLong Gold with DAPI, Invitrogen).
The mounted cells were observed under a fluorescence micro-
scope (Nikon) equipped with a digital camera (AxioCam,
Zeiss) with 20 objective and pictures taken in five different
areas that contained5100 DAPI-positive cells. Double positive
cells and DAPI-positive cells were counted. Data were ex-
pressed as a percentage of double-positive cells against
DAPI-positive cells: % positive cells = (number of double-posi-
tive cells/DAPI-positive cells  100). Data were collected from
three independent experiments.
Determination of p75NTR expression
in oligodendrocyte precursor/
oligodendrocyte cells
Cells were fixed with 4% paraformaldehyde for 20min and
then washed with PBS and treated with blocking buffer (10%
goat serum/0.1% BSA/0.01% TritonTM X-100) for 1 h at
room temperature. Anti-rabbit p75NTR Ab (1:1000 dilution;
COVANCE) was added and incubated overnight at 4 C. For
negative controls, no antibody was added. After washing cells
with PBS three times, secondary antibody (goat anti-rabbit
Alexa 488, 1:200, Molecular Probes) was added and incubated
for 1 h at room temperature. Cells were washed with PBS three
times and cover-slipped with mounting media (ProLong Gold
with DAPI, Invitrogen). The mounted cells were observed
under a fluorescence microscope (Nikon) equipped with a digi-
tal camera (AxioCam, Zeiss) with a 20 objective and pic-
tures were taken in five different areas containing4100
DAPI-positive cells. Double-positive cells and DAPI-positive
cells were counted, and data were expressed % double-positive
cells versus DAPI-positive cells (number of double positive
cells/DAPI positive cells  100). Negative controls were stained
with only secondary antibody. Data were collected from three
independent experiments.
CCI-TBI and drug treatment
To generate the TBI, a controlled cortical impactor (Custom
Design & Fabrication) was used as described previously (Inoue
et al., 2013). Surgical procedures were carried out aseptically
under anaesthesia induced and maintained by 2–3% of isoflur-
ane. The toe pinch-reflex test was used to determine the effect-
iveness of the anaesthetic prior to surgery. Lacri-Lube
ophthalmic ointment (Allergan Pharmaceuticals) was applied
to the eyes prior to surgery. Body temperature was monitored
using a rectal thermal probe and maintained at 37.5  0.5 C
using a heating pad. Animals were administered 25mg/kg of
cefazolin (Ancef, Novation, LCC) prior to surgery and for 3
days postoperatively. Rats were mounted in a Kopf stereotaxic
frame under isoflurane anaesthesia and maintained at 37.5 C.
A unilateral craniectomy was produced in the skull using a 6-
mm diameter trephine positioned from 3mm anterior to 3mm
posterior to bregma, and between 1.0mm and 7.0mm laterally
from bregma. Moderate contusion brain injury was generated
using the CCI device with a 5mm diameter impactor tip pos-
itioned perpendicular to the surface, of the left somato-motor
cortex, using a 2.0mm displacement at 4 m/s velocity, and a
dwell time of 150ms. The injury sites were closed and the
animals were recovered in a Thermocare Intensive Care
Unit with Dome Cover (Thermocare, Inclined Village). Sham-
injury controls had all procedures including the craniectomy
but without cortical contusion.
To infuse EVT901, rats had a jugular vein catheter placed
under anaesthesia. Animals were placed in a supine position, a
longitudinal cut was made in the skin, and muscles were re-
tracted to expose the left jugular vein. Polyethylene tubing
(0.58mm internal diameter  0.96mm outer diameter; BPE-
T50 Solomon Scientific) cut to a length of 12.5 cm was used
to introduce drugs (vehicle or EVT901) into the vascular
system. A 1.5 cm portion of the tubing was inserted into the
jugular vein, secured using a 4.0 silk suture and fed subcuta-
neously to the back of the animal, allowing easy access for
repeated drug administration. EVT901 doses (0, 1, 3, and
10mg/kg) were prepared and labelled to allow for blinding
of the investigators administering the drugs. The code used
for each group was revealed at the end of the study. The
total volume of solution was determined by the weight of
each rat. Five mg/kg (v/w) of prepared EVT901 (or vehicle)
was infused over 2min via an infusion pump (BS-300 Syringe
Infusion Pump, Braintree Scientific). EVT901 was infused once
per day for 7 days starting at 4 h post-injury. Blood was col-
lected by tail vein within 15min of the initial infusion on Day
1 and the final infusion on Day 7 to confirm infusion of
EVT901. Approximately 60 ml of blood was blotted on 903
protein saver cards (Whatman) and dried at room temperature.
Analysis of the coded blood spots showed that each drug treat-
ment level resulted in the predicted blood levels (not shown).
Sample size was determined by power calculations based on
previous studies (Inoue et al., 2013) (n = 8–12 per group).
Only data from animals surviving for the entire test period
were included in the statistical analysis. Overall survival rate
was 90%.
Western blot analysis of CCI-TBI
tissue
Rats were perfused with PBS at 1, 2, 8, and 14 days post-
injury. Brains were removed and the white matter region,
cortex, and hippocampus were dissected for protein prepar-
ation. The tissue was homogenized in protein lysis buffer
(1:5 ratio, Pierce IP Lysis buffer, Thermoscientific) including
proteinase/phosphate inhibitor (HaltTM Protease and
Phosphatase inhibitor cocktail, Thermoscientific), 5mM
EDTA and 1mM PMSF and sonicated at 40 amplitude, 10 s
pulse, two times. Protein lysate was obtained by centrifugation
at 13 000 rcf for 10min at 4 C. Protein concentration was
determined by the BCA protein assay kit (Pierce). Twenty
micrograms of protein was added with Laemmli sample
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buffer (Bio-Rad) including 20mM DTT and b-mercaptoetha-
nol and boiled for 5min. Protein was loaded onto 4–20%
tricine gel (Bio-Rad), electrophoresed, and transferred onto a
PVDF membrane. After blocking the membrane with blocking
buffer (Li-COR Bioscience), the membrane was incubated
overnight at 4 C with antibodies directed against p75NTR
(1:1000, COVANCE, Cat #. PRB-602C), proNGF (1:500,
Millipore, Cat #. AB9040), Cleaved caspase-3 (1:1000, Cell
Signaling, Cat #. 9664), and b-actin (1:2500, Sigma).
Membranes were washed three times for 5min with PBS, sec-
ondary antibodies (anti-rabbit IR680 and/or anti-mouse
IR800, 1:5000) were added and incubated for 1 h at room
temperature. After washing membranes with PBS three times
for 5min, membranes were scanned with an Odyssey scanner
(Li-COR Bioscience). Quantification was performed using the
Odyssey scanner software (Li-COR Bioscience). b-Actin served
as a loading control. The sample size was chosen based on
preliminary data (n = 3 per group).
Histology, immunocytochemistry and
cell counts for CCI-TBI animals
Rats were killed at 24 h or 8 days post-injury and transcar-
dially perfused with PBS, followed by 4% paraformaldehyde.
Brains were removed, post-fixed, and cryoprotected in 30%
sucrose. Sections of 30 mm were cut on a cryostat (Microm).
Sections were treated with blocking buffer (10% goat serum/
0.1% BSA/0.01% TritonTM X-100) for 1 h at room tempera-
ture and stained overnight at 4 C with antibodies against
p75NTR (1:200, COVANCE, Cat #PRB-602C), proNGF
(1:100, Millipore, Cat #AB9040), cleaved caspase-3 (1:100,
Cell Signaling, Cat #9664), APC (1:10, Millipore, Cat
#Ab16794), GFAP (1:100, Millipore, Cat #345860), and
CD11b (1:100, Serotec, Cat #MCA275R). After washing
with PBS three times, secondary antibodies (1:200; anti-
rabbit Alexa 488; Molecular Probes, 1:200; anti-mouse
Alexa 594; Molecular Probes) were added and incubated for
1 h at room temperature. Slides were washed with PBS three
times for 5min, and were mounted with mounting media
(ProLong Gold with DAPI, Invitrogen). Slides were analysed
using a fluorescence microscope (Nikon) and images were cap-
tures with a digital camera (AxioCam, Zeiss).
Volumetric analysis
The Cavalieri probe method
To determine if EVT901 affects tissue damage after TBI, the
estimated volume of the injured brain (including the 5mm
injured zone) was measured by systematic volumetric analysis.
Briefly, at 8 days after TBI, the brains of paraformaldehyde
perfused animals were collected and cut at 30 mm as described
above. For each rat, 15 brain tissue sections (every 10 sections
between + 2.2 and2.2mm from Bregma) were chosen for
stereological analysis and stained with Cresyl violet
(Fig. 4D). The Cavalieri principle was used to generate un-
biased estimates of volume using Stereo Investigator software
(MBF Bioscience). As a Cavalieri probe, a 200-mm square grid
was placed over the brain tissue section and all the grid points
that overlay the areas of interest were marked. Areas included
the hemisphere (Fig. 4B), cerebral cortex (Fig. 4C), and the
white matter including the corpus callosum (Fig. 4C). All 15
brain tissue sections were evaluated by marking the grid
points, which generate unbiased estimations of area. The
volume was estimated by summing the areas and multiplying
by the tissue thickness using Stereo Investigator software.
Gunderson coefficient of error, m = 1, was evaluated to deter-
mine the accuracy of the stereological estimation and
was50.05 (not shown) in this study (n = 8–12 per group).
Sample size was determined by power calculations based on
previous studies (Inoue et al., 2013) (n = 8–12 per group).
Stereological analysis
Counting APC-positive cells
To determine if EVT901 protects oligodendrocytes from TBI,
we quantify the number of oligodendrocytes in the white
matter by unbiased stereological assessment. Briefly, a total
of 10 brain sections were chosen for stereological analysis
(every 330mm interval between 1.5mm anterior to 1.5mm
posterior to Bregma). Free-floating brain sections were stained
with anti-CC1 antibody (APC clone) (1:100 dilution; Abcam,
Cat #Ab16794) overnight at 4 C. After washing with PBS,
tissues were incubated with biotinylated antibody
(VECSTAIN Elite ABC Kit, Vector Laboratories) for 30min
and visualized by 3,3’ diaminobenzidine (DAB) chromogen
(ImmPACTTM DAB Peroxidase substrate, VECTOR
Laboratories). To quantify the number of APC-positive cells
for unbiased assessment, systematic random sampling using
the optical fractionator method in the region of interest was
performed with Stereo Investigator (Fig. 4C). The white matter
was contoured with a 2 objective and cells counted with a
63 objective. A counting grid was set as 245mm  183 mm
and placed randomly over the contoured white matter (Zhao
et al., 2011). The counting frame was set as 30 mm  30 mm
with 3 mm guard zone (Lotocki et al., 2011). Section thickness
was measured at each counting site and the average tissue
thickness was computed for stereological calculation by
Stereo Investigator software. Average of tissue thickness was
18.95  0.45 mm (SEM). The total number of CC1-positive
cells was automatically calculated by Stereo Investigator
using the following equation: N =Q  1/ssf  1/asf  1/hsf
(N is total neuron number, Q is the number of neurons
counted, ssf is section sampling fraction, asf is the area sam-
pling fraction, and hsf is the height sampling fraction).
Coefficient of error, m = 1, was evaluated to determine the
precision of the estimation of the stereological measurement.
All Coefficients of error, m = 1, in each group was50.05 (not
shown; n = 5–7 per group).
Counting NeuN-positive cells
To determine if EVT901 preserves neuronal cells from TBI, we
quantified the number of NeuN-positive cell in the cerebral cortex
by unbiased stereological assessment. Briefly, seven brain sections
were chosen for stereological analysis (every 330mm interval from
between bregma levels +1.2 and1.2mm). Free-floating brain
sections were stained with anti-NeuN antibody (1:100 dilution;
Millipore, Cat #ABN90) overnight at 4 C. After washing with
PBS, tissues were incubated with biotinylated antibody
(VECSTAIN Elite ABC Kit, Vector Laboratories) for 30min
and visualized by DAB chromogen (ImmPACTTM DAB
Peroxidase substrate, VECTOR Laboratories). To quantify the
number of NeuN-positive cells, the optical fractionator method
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was used by Stereo Investigator. The rhinal fissure was used as a
landmark to identify the lateral aspect of the neocortex (Fig. 4C)
(Weskamp and Reichardt, 1991). The cortical region was con-
toured to the border of rhinal fissure with a 2 objective and
counting was performed with 63 objective. The counting grid
was set as 350mm  265mm and placed randomly over the con-
toured cortical region (Weskamp and Reichardt, 1991). The
counting frame was set as 50mm  50mm with a 3mm guard
zone. The section thickness was measured at each counting site
and the average tissue thickness was computed for stereological
estimate calculation by Stereo Investigator software. Average
tissue thickness was 19.02  0.2675mm (SEM). The total
number of NeuN positive cells was automatically calculated by
Stereo Investigator using the following equation: N =Q  1/
ssf  1/asf  1/hsf (N is total neuron number, Q is the
number of neurons counted, ssf is section sampling fraction, asf
is the area sampling fraction, and hsf is the height sampling frac-
tion). Coefficient of error, m = 1, in this study was50.05 (data
not shown; n = 4 per group).
Determination of myelin loss in white
matter
To determine the effect of TBI on myelin loss, eriochrome
cyanine was used for staining. Briefly, brain tissue sections
were chosen from bregma900mm, where the most damaged
white matter area based on unbiased systematic volumetric
analysis using Cavalieri probe (Supplementary Fig. 2). After
defatting with acetone, tissues were stained with eriochrome
cyanine solution (0.3% eriochrome cyanine, 0.5% H2SO4, and
10% iron alum) for 30min at room temperature in 5% iron
alum solution until white matter (blue) was clearly differen-
tiated from grey matter. Then tissue sections were placed in
borax-ferricyanide solution (1% borax and 1.5% potassium
ferricyanide) for 10min to complete differentiation. After rin-
sing with water, tissues were dehydrated and mounted with
DPX mounting media (Sigma). Entire brain tissue images
were captured with 10 magnification and stitched by BZ-
8100 (BIOREVO microscope, Keyence). To measure intensity
of eriochrome cyanine staining, NIH ImageJ software was
used. Briefly, the entire brain images were opened with
ImageJ software, converted to 8 bit image, and contoured
white matter areas in ipsilateral and contralateral hemisphere
were indicated as the region of interest. To obtain only myelin-
positive signal, the image was adjusted using bright/contrast by
setting threshold to the grey scale range of 70–250 (Image
J4 Image4 adjust images). Then the region of interest was
selected and the integrated density measured (Image
J4 Integrated density4 analyze4measurement). The inte-
grated density value for contralateral was used for the internal
control. Data are presented as a percentage (intensity of ipsi-
lateral/intensity of contralateral)  100 (n = 5 per group). The
sample size was chosen based on preliminary data (n = 5 per
group).
Determination of microglia
activation in white matter
To estimate microglial activation, we used a proportional area
measurement modified from previous reports (Popovich et al.,
1999; Zhang et al., 2011). Five brain tissue sections at 600-mm
intervals from Bregma +1.2mm to1.2mm were measured
from each rat. Briefly, brain tissue sections were treated with
peroxidase block (Dako EnVisionTM+ System-HRP, DAKO)
for 5min, washed with PBS, and then incubated with CD-
11b Ab (1:100 dilution, AbD Serotec, Cat #MCA275R) for
1 h at room temperature. After washing with PBS, peroxidase-
labelled polymer (Dako EnVision + System-HRP, DAKO) was
applied for 30min at room temperature. Tissues were washed
with PBS and then visualized with DAB chromogen for 10min.
The reaction was stopped with distilled water. The stained
sections were observed on a Zeiss microscope. For assessing
CD11b-positive cells in the white matter, two different areas
(157.5  101.6mm) in the ipsilateral and contralateral side of
brain from the corpus callosum were photographed under a
40 objective using a digital camera (Retiga EXi Fast1394,
Qimaging). To measure the proportional area of reactive
microglia, we used threshold measurement by MetaMorph
software (Molecular Devices). Briefly, images were opened
with MetaMorph software and the intensity of the back-
ground was measured using ‘Region Measurement’. Using
‘Set Color Threshold’, the threshold was set on the CD11b-
positive signal, while the pre-measured background intensity
was set as baseline (Metamorph4 Set Color threshold).
Once threshold was set, CD11b-positive signal was measured
using Region Measurement. Data are presented as percentage
(threshold area of CD11b-positive/total area)  100 (n = 5 per
group). The sample size was chosen based on preliminary data
(n = 5 per group).
Behavioural evaluation for motor
recovery
The paw placement test was performed as previously described
(Inoue et al., 2013). Briefly, rats were placed in a clear plastic
cylinder. The spontaneous behaviour of the rats was recorded
with a digital camera for 3min, and the number of times the
rat placed its left, right, or both forepaws against the cylinder
during weight supported movements was determined.
Individual placements were scored as ‘left’, ‘right’, or ‘both’.
Scoring was performed using video playback by two trained
raters independently in a blinded manner. Rats were tested
before surgery and on Days 2 and 7 after TBI. Sample size
was determined by power calculations based on previous stu-
dies (Inoue et al., 2013) (n = 8–12 per group).
Fluid percussion traumatic brain
injury and outcome measures
Male Sprague Dawley rats (strain RjHan; Janvier) (170–230 g)
were anaesthetized with sodium pentobarbital for trauma,
placed in a stereotaxic frame, and a hole (4mm in diameter)
was made at the level of the right parietal cortex (the centre
being located 3.5mm posterior to bregma, 7mm lateral to the
midline and 3.5mm below the upper surface of the skull). A
1.6mm internal diameter Teflon tube was placed in contact
with the dura and fixed into the craniotomy with dental acrylic
cement. The tube was connected to a Beckman HPLC pump
and was filled with sterile injectable water. An FPI of moderate
intensity (5 bar) was induced by a brief opening of the elec-
tronically controlled solenoid valve (100ms). Thereafter, the
tubing was removed, the scalp sutured and animals placed
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under a heating lamp for recovery from anaesthesia. The mor-
tality rate was 5%. The severity of injury was confirmed by
assessing cognitive deficits. Sham rats were surgically prepared
in the same manner but did not undergo craniotomy. EVT901
or its vehicle was administered orally by intragastric gavage
(5ml/kg in a solution of 0.6% methylcellulose/0.5% Tween
80), once a day, 24 h after the surgery, and for 23 days.
Behavioural evaluation of memory
deficits
Object recognition test
Memory assessment was performed 5 days after the end of
treatment on Day 28 post-injury. The test consisted of three
sessions. The first session was for habituation (exploration for
3min, record of the time spent in active movements). The
second at 24 h later, was the acquisition session; the rat was
placed in the box with two identical objects located in opposite
corners, and the time to achieve 20 s exploring those two ob-
jects was recorded (limit of 6min). Rats were replaced in the
box 1h later, for the third recall session of 5min, with a pre-
viously presented familiar object and a novel object. Time
spent exploring the familiar (F) and the novel (N) objects
was recorded. Others parameters calculated from the recall
session: total exploratory time (N + F) and the novelty index
(N F/N + F).
Conditioned freezing response test
Memory deficits were evaluated using the conditioned freezing
response test. Rats were conditioned to associate the context
with a foot shock, and then tested for fear-associated freezing
to the context. Briefly, two sessions, 24 h apart were used.
First, rats were introduced to the experimental box where
they received a scrambled electric foot-shock (0.6mA, 1.5 s).
In the second session, the rats were replaced in the same box
for 3min, and the duration of freezing (complete lack of move-
ment except for breathing) was recorded.
Behavioural evaluation of seizure
susceptibility
Epileptogenesis
To detect any enhanced seizure susceptibility in post-TBI rats,
a kainate sensitivity test was performed 42 days after the trau-
matic injury and 5 days after the last administration of the
compound EVT901 (1mg/kg/day, oral administration for 42
days). Evaluation of the increased susceptibility of rats to
seizure induction by kainate was determined after a single in-
jection of sub-convulsant dose of kainate (8mg/kg, intraperi-
toneally). Movement was evaluated from 45min to 3 h 45min
post-kainate injection: each rat was observed and convulsions
were scored into five classes by a standard method (Racine’s
score) (from stage 1: immobility, to stage 5: forelimb clonus,
rearing and loss of postural tone). For each group, a status
epilepticus was defined, corresponding to the per cent of rats
that reached continuous seizure activity in the different groups.
Immunohistochemistry
p75NTR and Fluoro-Jade staining
Free-floating tissue sections were incubated overnight at 4 C
with anti-p75NTR antibody (1:1000, Millipore) in PBS-T/
serum 1%, then with secondary antibody (Vector Vectastain
ABC kit) and avidin-biotin-peroxidase complex (Vector
Laboratories). Sections were visualized using a DAB substrate
kit for peroxidase (DAB kit, DAKO), mounted on glass slides,
air dried, alcohol dehydrated and cover-slipped with Eukitt
mounting medium (Eukitt EMS). For Fluoro-Jade staining,
tissue sections were directly mounted onto DAKO-Flex
slides, hydrated and incubated in a solution of potassium per-
manganate. After incubation in a solution of Fluoro-Jade B
(Chemicon), sections were air-dried, immersed in xylene,
cover-slipped as previously, and visualized using FITC fluores-
cence microscopy. Digital images were collected and Fluoro-
Jade B-positive cells were subsequently counted using Explora
Nova software; averages were used for statistical analysis.
Randomization and blinding
All animal studies were performed with randomized treatment
allocation and outcomes assessed by experimenters blind to
condition.
Statistical analysis
Analysis of all biochemical, histological and behavioural data
was performed in SPSS v.19 (IBM) by an independent statisti-
cian. One-way, two-way (or higher order) balanced, factorial
analysis of variance (ANOVA; SPSS General Linear Model
command) was used to explicitly test each factor in the
balanced factorial experimental designs. The statistical ap-
proach ensured two-tailed, balanced testing of main effects
and interactions across all factorial combinations of treat-
ments. Technical replicates and independent experiments
were statistically treated as random effects, thereby correcting
for technical variance to directly test treatment effects con-
served across replicates. Comparison of two groups was per-
formed by an unpaired, two-tailed Student’s t-test. For
behavioural analysis of cognitive/motor function, mixed factor-
ial repeated measures ANOVA was used. Sample sizes (n) were
justified by power calculations and all analytics were applied
after checking for statistical assumptions (normality, homogen-
eity of variance, sphericity). Statistical significance was defined
at P4 0.05. Data are expressed as means  SEM. F-values
and degrees of freedom are reported in figure legends.
Results
EVT901 inhibits p75NTR signalling,
blocks apoptosis, and activates TrkA
To determine whether a small molecule could bind to
p75NTR and disrupt the preassembly step (Chan, 2007),
we set up a screen to detect protein/protein interaction with
reliable quantification. The soluble truncated form of
p75NTR, containing only the four CRDs fused to alkaline
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phosphatase (AP-p75NTR), was used as ligand and probe
to detect p75NTR oligomerization on SK-N-BE human
neuroblastoma cells stably transfected with full length-
p75NTR (SK-N-BE-p75NTR). More than 400 molecules,
selected from a library of compounds active on a pheno-
typic model of neurogenesis, were screened for their ability
to inhibit the pre-oligomerization of p75NTR (ligand-
independent). Thus, a dedicated chemical program allowed
us to select new leads characterized by aryl substituted pi-
perazine and showing nanomolar activity. From the
structure/activity relationship analysis, an oriented second
back-screening campaign, in particular with introduction of
bridged piperazines replacing the piperazine moiety, led us
to select a new chemical series [1-(phenyl-3, 6-dihydro-2H-
pyridinyl)-2-(aryl-bridged piperazines)-ethanone] with high
potency, specificity and selectivity; those compounds were
also screened in vitro to inhibit apoptosis in neuroblastoma
cells. Through the optimization process, we identified
EVT901 (Fig. 1J) as a highly active compound with sub-
nanomolar potency; and a full characterization of its
selectivity and ADME (absorption, distribution, metabolism
and excretion) in vitro and in vivo properties was carried
out. EVT901 showed a high ability to inhibit the binding of
AP-p75NTR to p75NTR in a dose-dependent manner,
with sub-nanomolar potency (IC50 of 0.21  0.04 nM)
(Fig. 1A). EVT901 also alters NGF binding to p75NTR
(Fig. 1B).
To determine whether a specific self-association domain
(PLAD) is present on the p75NTR and if EVT901 can
interfere with its oligomerization (Chan et al., 2000), we
co-expressed full-length HA-p75NTR and Flag-p75NTR
tagged receptors in HEK293T cells. High levels of Flag-
p75NTR association with the HA-p75NTR were observed
when both receptors were co-expressed, demonstrating that
p75NTR is able to self-oligomerize independently of ligand
binding (Fig. 1C). Interestingly, EVT901 dose-dependently
reduced this association, suggesting that EVT901 can inter-
fere with p75NTR pre-oligomerization. To confirm that
EVT901 interferes directly at the level of a PLAD (Gentry
et al., 2004), we designed different mutated and chimeric
receptors (Fig. 1E). Transfection efficiency of these chimeric
receptors was confirmed using an anti-HA antibody to
detect surface expression using flow cytometry.
Expression of the various constructs was between 85%
and 95% of cells (data not shown). Consistent with a pre-
vious study (Ye et al., 1999), overexpression of full-length
p75NTR induced spontaneous apoptosis, which was sig-
nificantly abrogated by EVT901 at 100 nM (Fig. 1D).
Overexpression of a deleted form of p75NTR (CRD1-
p75NTR) also induced high levels of apoptosis, which
was strongly reduced in the presence of EVT901.
Moreover, EVT901 was not able to abrogate CD40-
induced apoptosis, clearly suggesting its specificity for
p75NTR. Although specific deletions may disrupt receptor
structure, we generated a chimeric receptor by exchanging
the first CRD of CD40 receptor with the CRD1 of
p75NTR and confirmed that expression of this chimeric
receptor on HEK cells induced strong spontaneous apop-
tosis, similar to wild-type cells (Fig. 1D and E). In this
model, EVT901 showed anti-apoptotic activity confirming
that the site of interaction of EVT901 is located on the
CRD1 of p75NTR (Fig. 1D). The specificity of EVT901
to p75NTR versus other members of the TNFR superfam-
ily (TNFR1, TNFR2, HVEM, 4-1BB, LTbR, DR5, BCMA,
FAS) was further confirmed by demonstrating that EVT901
does not inhibit apoptosis of HEK293T cells induced by
overexpression of these receptors (Fig. 1F). As a follow-
up to the p75NTR-overexpression models, it was essential
that EVT901 was also able to abrogate p75NTR signalling
in a cell type expressing endogenous p75NTR. Therefore,
we confirmed the neuroprotective effects of EVT901 on
SH-SY5Y cells, where apoptosis is induced by pro-NGF
(IC50 of 0.51  0.16 nM) (Fig. 1G).
Well known to exhibit prevalent b-sheet structures and to
form fibrillar aggregates, the prion protein (PrP106–126) and
amyloid (amyloid-b1–40) peptides induce pro-apoptotic sig-
nalling via p75NTR. We hypothesized that the interaction
site(s) of these peptides on p75NTR are different from that
of the neurotrophins, and could be located in the CRD1
domain of p75NTR. We first evaluated the effect of these
two aggregated peptides on apoptosis in SH-SY5Y cells.
Incubation with PrP106–126, or amyloid-b1–40, increased
cell death (not shown). Interestingly, EVT901 was able to
strongly reverse apoptosis induced by these two aggregated
peptides with IC50s of 0.69  0.30 nM for PrP106–126 and
0.42  0.11 nM for amyloid-b1–40 (Fig. 1G). Moreover, the
potency of EVT901 against apoptosis induced by these
peptides suggests that the functional epitope on p75NTR
interacting with PrP106–126 and amyloid-b1–40, is located on
the CRD1 domain. This hypothesis was further supported
by the pro-apoptotic efficacy of these peptides on the short
form of p75NTR containing only CRD1 in the extracellu-
lar part.
Previous findings suggest p75NTR mediates NGF-
induced neuronal cell survival and neurite outgrowth by
regulating the TrkA-mediated signalling pathway. We
tested whether EVT901 interferes with TrkA-dependent
neurite outgrowth on SH-SY5Y cells expressing both
TrkA and p75NTR. Increasing concentrations of EVT901
induced extensive neuritogenesis in a dose-dependent
manner, as compared to untreated controls (Fig. 1H), sug-
gesting that EVT901 can modulate TrkA activation by
facilitating the interaction of p75NTR monomers with
TrkA. To further validate this hypothesis, we showed that
the level of TrkA phosphorylation is strongly increased by
stimulation with rhNGF (Fig. 1I), and EVT901 dramatic-
ally increased TrkA phosphorylation after 3 days of treat-
ment, correlating with the induction of neurite outgrowth
(Fig. 1I).
ProNGF has been shown to induce caspase activation
and apoptosis in cultured oligodendrocytes via p75NTR
(Beattie et al., 2002). Here we tested if EVT901 would
reduce this pro-NGF-induced apoptosis in mature oligo-
dendrocytes and OPCs in culture, and show that adding
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proNGF for 24 h increased p75NTR expression and cas-
pase activation, and a wide dosing range of EVT901 in-
hibited both (Fig. 2). Thus, EVT901 may provide
protection from proNGF toxicity by both reducing expres-
sion of p75NTR and by blocking proNGF-induced
p75NTR oligomerization and apoptotic signalling.
EVT901 is protective in a unilateral
CCI-TBI model and improves
outcomes
CCI-TBI transiently increased p75NTR protein level at 1
and 2 days post-injury in the ipsilateral white matter
(Fig. 3A and B). Immuno-staining revealed that p75NTR
was co-localized in CC1 positive cells at 24 h following
CCI-TBI, suggesting that injury induces p75NTR-expres-
sion in oligodendrocytes, as reported after spinal cord
injury (Beattie et al., 2002) (Fig. 3B). p75NTR was not
co-localized in GFAP+ astrocytes (not shown). Western
blot analysis showed a rapid (and longer) transient increase
in proNGF after TBI, returning to normal at 14 days
(Fig. 3C) and this could induce apoptosis in oligodendro-
cytes in the subcortical white matter. Indeed, western blots
using an antibody to cleaved caspase-3 revealed a signifi-
cant increase in expression by 8 days after TBI (Fig. 3E),
similar to that seen in the dorsal columns after spinal cord
injury (Beattie et al., 2002; Sun et al., 2010). Evidence for
co-localization of CC1 and cleaved caspase-3 in immunos-
tained sections was seen as early as 1 day post-TBI (Fig.
3F). In addition, p75NTR protein levels were significantly
increased in both cortex after TBI (Supplementary Fig. 1),
suggesting that p75NTR is also involved in neuronal cell
death in vivo.
Cerebral, cortical, and subcortical white matter volumes,
measured using unbiased stereological methods at 8 days
post-TBI (Fig. 4), were significantly reduced by TBI, and
EVT901 dose-dependently mitigated the loss (Fig. 4F, G
and Supplementary Fig. 2A and B). Using stereological es-
timates of oligodendrocytes in the subcortical white matter
Figure 2 EVT901 blocks proNGF-mediated caspase activity and p75NTR expression in OPCs and oligodendrocytes in vitro and
reduces proNGF-induced cell death. (A) Immunostaining showed that treatment with pro-NGF (50 ng/ml) induced caspase-3 activity in
OPCs in vitro. (B and C) Caspase activity was measured by counting positive cells using the FLICA assay. Pro-NGF (50 ng/ml) increased caspase
activity in cultured OPCs and oligodendrocytes. However, EVT901 added to the medium reduced the percentage of caspase-positive cells in a
dose-dependent manner for OPCs and oligodendrocytes [one-way ANOVA, F(7,67) = 10.02, P5 0.0001 for OPCs and F(7,65) = 10.55,
P5 0.0001 for oligodendrocytes]. (D–F) Both OPCs and oligodendrocytes expressed p75NTR in a small percentage of cells in vitro, this was
increased significantly by the addition of pro-NGF, and co-incubation with EVT901 reduced or inhibited p75NTR expression. Note that mature
NGF (mNGF) had no effect on apoptosis or p75NTR expression. One-way ANOVA, F(7,105) = 20.30, P5 0.0001 and F(7,98) = 5.68, P5 0.0001
for OPCs and oligodendrocytes, respectively. P5 0.0001 compared to cells alone; #P5 0.05, ##P5 0.005, ###P5 0.0001 compared to 0 nM
EVT901. Scale bar = 30mm.
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Figure 3 Induction of p75NTR and proNGF in the white matter (corpus callosum) after CCI-TBI. (A–D) Immunoblot analysis
showed that both p75NTR and proNGF protein levels are increased after TBI in the ipsilateral white matter as compared to uninjured (UN) and
sham injured tissue. Two-way ANOVA, (A) for p75NTR: side, F(1,12) = 92.42, P5 0.0001; time, F(5,12) = 32.32, P5 0.0001; (C) for proNGF:
side, F(1,12) = 126.54, P5 0.0001; time, F(5,12) = 18.18, P5 0.001. In ipsilateral white matter, p75NTR and proNGF are significantly increased
[F(5,12) = 32.55, P5 0.0001 and F(5,12) = 11.72, P5 0.0001, respectively]. (B) P75NTR immunoreactivity is co-localized with CC1 expression in
cells with oligodendrocyte morphologies (arrowheads). Scale bar = 20 mm. (D) ProNGF immunoreactivity is co-localized in CD11b-positive and
GFAP-positive cells (arrowheads), suggesting that microglia and astrocytes are responsible for proNGF expression in the corpus callosum at 1 day
after TBI. Scale bars = 50mm. (E) Immunoblot analysis showed that TBI increased the cleaved caspase-3 expression on the ipsilateral side
compared to the contralateral side at 8 days after injury [side, F(1,12) = 6.78, P5 0.05; time, F(5,12) = 6.02, P5 0.01]. In the ipsilateral white
matter, cleaved caspase-3 protein level is significantly increased [F(5,12) = 6.02, P5 0.01]. P5 0.05, P5 0.005, P5 0.0005, ##P5 0.01
compared to sham; n = 3/group; Error bars indicate SEM. (F) Cleaved caspase-3 immunoreactivity is co-localized in CC1 positive oligo-
dendrocytes (arrowheads). Scale bar = 50mm. P5 0.05, P5 0.005, P5 0.0005, ##P5 0.01 compared to sham.
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Figure 4 EVT901 treatment reduced atrophy in grey and white matter at 8 days post injury. (A) The region of interest (ROI)
included tissue from 3 mm anterior to 3 mm posterior to bregma. (B and C) Illustration of representative brain figures of the hemisphere (B) and
cerebral cortex and white matter (C), where stereological methods were used to estimate tissue volume by counting Cavalieri markers using
Stereo Investigator. (C) The region of interest included the cerebral cortex from the midline to the rhinal fissure (small arrowhead); the ipsilateral
cerebral cortex is indicated in red versus the contralateral cerebral cortex in blue, and ipsilateral white matter is indicated in pink whereas light
blue indicates contralateral white matter. (D) Representative brain tissues stained with Cresyl Violet. Scale bar = 1 mm. (E) Total estimated volume
was measured in each hemisphere. Total volume did not change between the ipsilateral and contralateral hemispheres at 8 days post-injury. (F)
Total cortical volume estimates revealed significant atrophy of cortex on the ipsilateral but not contralateral side after TBI [two-way ANOVA, side,
F(1,45) = 101.09, P5 0.001]; P5 0.05 compared to sham. However, EVT901 treatment was protective on the ipsilateral side [dose  side,
F(4,45) = 2.69, P5 0.05]; n = 8–12 per group. (G) Total white matter volume was also significantly reduced ipsilateral to the injury [side effect,
F(1,45) = 17.51, P5 0.001; dose effect, F(4,45) = 2.22, P4 0.05]. EVT901 treatment preserved white matter volume on the ipsilateral side
[side  dose, F(4,45) = 2.98, P5 0.05]. P5 0.05 compared to sham, #P5 0.05 compared to 0 mg/kg. Error bar indicates  SEM.
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(Fig. 5A and B), TBI significantly reduced CC1-positive
oligodendrocytes and EVT901 treatments partially pre-
vented this loss. Stereological counts of spared NeuN-posi-
tive cells in the cortical lesion area showed significant loss
after TBI, and a protection after EVT901 treatment (Fig.
5C and D). Further, EVT901 treatment preserved myelin
when compared to vehicle controls (Fig. 6A and B).
Using OX-42 staining density as a measure of microglial
activation in tissue sections from vehicle and EVT901-trea-
ted (1mg/kg) animals (Fig. 6C and D), EVT901 reduced
microglial activation. Microglial activation has been
shown previously to be associated with the loss of CC1
positive oligodendrocytes by apoptosis (Shuman et al.,
1997; Sun et al., 2010).
Figure 5 EVT901 treatment inhibits cell death in the cerebral cortex and underlying white matter at 8 days after CCI-TBI. (A)
Stereological sampling of total number of oligodendrocytes (CC1-positive cells, arrowheads in the inset) in white matter was evaluated on DAB
immunostained sections. (B) Cell numbers were estimated using unbiased stereology by optical fractionation (see ‘Materials and methods’ section;
Stereo Investigator). TBI significantly reduced the number of CC1-positive cells in the white matter ipsilateral to the TBI. Two-way ANOVA, side,
F(1,28) = 17.51, P5 0.0001. EVT901 treatment preserved the number of oligodendrocytes ipsilateral to the lesion [dose  side, F(4,28) = 2.69,
P = 0.05]. n = 5–7 per group. Error bar indicates  SEM. A subsequent t-test showed a significant difference between 0 and 1 mg/kg on the
ipsilateral side (P5 0.05). (C) Neuronal loss was evaluated in sections immunostained for NeuN using DAB; cell staining in the ipsilateral
perilesional cortex is shown for representative vehicle and EVT901-treated cases. Arrows indicate individual neurons. (D) Unbiased stereological
analysis by optical fractionation was used to count NeuN-positive cells (see ‘Materials and methods’ section; Stereo Investigator). TBI caused a
marked reduction in the number of cortical neurons counted ispilaterally versus contralaterally. Two-way ANOVA, side, F(1,6) = 28.65, P5 0.01.
However, EVT901 treatment (1 mg/kg) protects NeuN-positive cells on the ipsilateral side [F(1,6) = 5.89, P = 0.05]. P5 0.05 compared to
vehicle, n = 5. Scale bar = 10mm.
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Paw use for exploration in a cylinder is significantly
reduced on the side contralateral to a cortical injury
(Inoue et al., 2013). This was also partially preserved by
EVT901 treatment (Supplementary Fig. 2E).
Oral EVT901 improves long-term
outcomes in another TBI model
The results of our CCI-TBI studies provide evidence for a
neuroprotective effect of EVT901 when the drug is given
intravenously over 7 days; there is a clear positive effect on
oligodendrocytes and white matter integrity, neuronal
protection, and at least one sensorimotor function test.
To examine the generality and persistence of these results,
EVT901 was administered over a longer time course in
another TBI model where trauma is induced by a focal
lateral fluid percussion injury of the parietal cortex (FPI-
TBI).
Similar to the effects of CCI-TBI, FPI-TBI produced an
early expression of p75NTR at 1–2 days post-injury in the
dentate gyrus, a structure where damaged neurons were
also observed (Fig. 7A and B). Particularly vulnerable to
FPI-TBI, the thalamus manifested marked positive
Fluoro-Jade staining at 14 days post-TBI (Fig. 7C).
EVT901 significantly decreased Fluoro-Jade-positive cells
Figure 6 EVT901 treatment spares myelin and reduces microglial activation at 8 days after CCI-TBI. (A and B) Eriochrome
cyanine staining showed a dramatic loss of myelin staining after CCI-TBI that was significantly reversed by 7 days of EVT901 treatment (1 mg/kg).
Intensity measurements of staining in the white matter (outlined area) ipsilateral to the injury as a proportion of the same area on the
contralateral side, revealed a significant effect of EVT901 treatment. n = 3–5/group. Two tailed t-test, P5 0.05. Scale bar in A = 1 mm. (C) Brain
tissue sections were immuno-stained with OX-42 to reveal the presence of microglia. Representative sections showing staining in the corpus
callosum are shown for vehicle and EVT901-treated (1 mg/kg) subjects. Both DAB (middle) and fluorescent (OX-42 in red, DAPI in blue)
immunostained sections are shown. Scale bars = 50mm. (D) Microglial activation, measured by proportional area of OX-42 staining, was increased
ipsilateral to the lesion; EVT901 treatment reduced OX-42 staining [two way ANOVA, side, F(1,8) = 44.96, P5 0.002; dose, F(1,18) = 10.11,
P5 0.05]. There was also a significant dose  side interaction in microglia activation with EVT901 treatment [F(1,8) = 40.85, P5 0.001].
##P5 0.01 compared to vehicle; n = 3–5/group. Bars represent mean  SEM.
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(324.3  54.1 cells) in the dorsal thalamus on the injured
side as compared to the vehicle (741.8  138.4 cells)
(Fig. 7D).
Furthermore, EVT901 administered orally beginning at
24 h and then daily for 23 days, dose-dependently
restored object recognition performance and significantly
improved the ability of rats to discriminate between
objects compared to sham-treated animals (Fig. 8A–C).
Time spent by treated rats on novel versus the familiar
objects was significantly and dose-dependently increased
at 1 and 3mg/kg/day, and full recovery was observed
after 23 days exposure (Fig. 8A and B). There was a sig-
nificant increase in the novelty index, as reflected by total
exploration time (Fig. 8C). FPI-TBI induced a 75%
reduction in the freezing response compared to
sham; EVT901 significantly reinstated freezing dur-
ations at 0.3 and 1mg/kg/day (84% and 88% recovery,
respectively) (Fig. 8D). These studies suggest
that EVT901 abrogates memory deficit induced by FPI-
TBI.
TBI has been associated with increased seizure activity, so
the effect of EVT901 treatment on hypersensitivity to a
pro-convulsive agent was evaluated. Six weeks after
injury, a subconvulsive dose of kainate elicits full-blown
generalized tonic-clonic seizures (status epilepticus) in
90% of the rats with TBI (Fig. 8F). EVT901 treatment
significantly decreased the intensity of post-TBI seizures
(Fig. 8E), as well as the susceptibility to post-TBI seizures
(Fig. 8F), further reinforcing EVT901’s pharmacological
potential for treating CNS trauma.
Figure 7 Acute expression of p75NTR after FPI-TBI and reduction of neurodegeneration with EVT901 in vivo. (A)
Immunohistochemical expression of p75NTR at 1–2 days in the dentate gyrus of TBI rats using specific anti-p75NTR antibody. (B) Representative
photomicrographs (original magnification 10) of Fluoro-Jade staining of damaged neurons in the granular layer of the dentate gyrus in FPI-TBI
rats 1 week post-injury. (C) Representative photomicrographs of Fluoro-Jade-stained sections from the thalamus 14-days post-trauma (ipsi-
lateral versus contralateral to the injury). (D) Quantification of Fluoro-Jade B-positive degenerating cells in the thalamus of FPI-TBI rats after
EVT901 treatment. Following Fluoro-Jade staining, the digital images were collected and the damaged cells were quantified using Explora Nova
Software. Three mg/kg/day of EVT901 protected neurons in the thalamus after TBI [one-way ANOVA, EVT901 effect, F(3,18) = 8.46, P = 0.001].
#P5 0.05 and ##P5 0.005 compared to sham. P5 0.01 compared to vehicle. n = 5–7/group. Bars represent mean  SEM.
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Discussion
The present results provide evidence that interfering with
the oligomerization of p75NTR using the novel compound,
EVT901 that interacts with the CRD of the extracellular
domain of the molecule, is neuroprotective. P75NTR is
structurally and functionally related to the TNFR super-
family. Although oligomerization is considered as the first
signalling event induced by TNFRs, several studies indicate
the presence of a pre-ligand binding assembly domain
(PLAD) within the first cysteine-rich domain (CRD1) of
the TNFR extracellular domain that mediates the pre-
assembled oligomerization of the receptors prior to ligand
stimulation (Chan, 2007). Such a PLAD domain has not
been identified in p75NTR. Further, part of the pre-ligand
binding oligomerization also has been attributed to cysteine
bond formation in the transmembrane domain of p75NTR
(Vilar et al., 2009, 2014). However, reports show that mu-
tations in CRD1 abrogate neurotrophin binding to the re-
ceptor, consistent with the possibility of an assembly event
mediated by CRD1 as prerequisite for ligand binding
(Baldwin and Shooter, 1995). In addition, a PLAD peptide
from TNFR1 blocks TNF or collagen-induced arthritis in
vivo, highlighting the PLAD region as an interesting
pharmacological target for TNFRs (Deng et al., 2005).
In this context, we developed a novel screening assay
based on specific receptor binding that focused on the
ligand-independent oligomerization of the p75NTR. Our
Figure 8 EVT901 improves functional recovery at 23 days after FPI-TBI and reduces post-TBI seizure activity. (A–C)
Improvement in cognitive function after FPI-TBI evaluated by the object recognition test. Rats with a FPI-TBI or sham surgery were treated orally
with vehicle alone or different doses of EVT901 (0.1, 0.3, 1 and 3 mg/kg) at 24 h post-surgery and once daily for 23 days. Recognition memory was
evaluated using the Novel Object Recognition Test. (A) Time spent exploring novel (N) objects was recorded and expressed in seconds. There is
a significant EVT901 effect on the novel object recognition test [two-way ANOVA with repeated measurement, F(4,52) = 2.87, P5 0.05].
P5 0.05 compared to 0 mg/kg. (B) There is no effects on familiar object recognition test [F(4,52) = 1.10, P = 0.37]. (C) The novelty index (N – F/
N + F) was significantly reduced by TBI [F(1,52) = 12.73, P5 0.001]. EVT901 treatment improved recognition memory function as measured by
the novelty index [F(4,52) = 6.59, P5 0.0001] #P5 0.05 compared to sham; P5 0.05 and P5 0.005 compared to 0 mg/kg; n = 9–10/group. (D)
Improvement in recovery after TBI evaluated by the conditioned freezing response. TBI significantly reduced freezing responses [F(1,55) = 13.84;
P5 0.001], while treatment with EVT901 preserved the freezing response [F(3,55) = 5.68: P5 0.01]; ##P5 0.005 compared to sham; P5 0.005
compared to 0 mg/kg; n = 12/group. (E) Inhibition of kainate-induced seizure hypersensitivity after TBI by EVT901 (1 mg/kg). Evaluation of the
increased susceptibility of rats to seizure induction by kainate was determined after a single injection of a sub-convulsant dose of kainate (8 mg/kg,
intraperitoneally) in the different groups at 6 weeks after FPI-TBI. Seizure intensity was measured by Racine’s score from 45 min to 3 h 45 min
post-kainate injection. n = 10/group. There were significant time, EVT901, and time  EVT901 effects [two-way ANOVA with repeated meas-
urement, time effect; F(11,297) = 24.90 P5 0.0001, EVT901 effect; F(2,27) = 11.78, P5 0.0001, time  EVT901 effect; F(22,297) = 6.16,
P5 0.0001]. ###P5 0.0001 compared to sham, P5 0.05 compared to TBI. (F) For each group, we defined a status epilepticus (SE) corres-
ponding to the per cent of rats that reached continuous seizure activity in the different groups. Note that kainate treatment induced high numbers
of seizure incidence (90%) in TBI-vehicle group, while EVT901 treatment reduced it to 40%. Results are given as mean  SEM.
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unpublished data indicated that consistent with previous
findings (Vilar et al., 2009), the CRD1 domain is important
for oligomerization for inducing apoptosis with a mutant
lacking CRD1 domain (data not shown). Therefore, our
study first identified a potent small molecule, EVT901,
which directly inhibits the pre-oligomerization of the
p75NTR through its extracellular domain (CRD1
domain) at sub-nanomolar concentration.
Interestingly, a very recent study suggests that p75NTR
coexists as a trimer along with a monomeric form at the
cell surface (Anastasia et al., 2015). However, trimerization
was found not to be required for signalling (Anastasia et
al., 2015). The authors suggest that monomers of p75NTR
are sufficient to induce apoptotic cell death and that oligo-
merization of p75NTR prevents cell death (Wang et al.,
2000; Anastasia et al., 2015). Although we have not
tested whether EVT901 affects trimerization of p75NTR,
the inhibition of p75NTR oligomerization by EVT901 was
supported by additional studies showing an inhibition of
what we interpreted as oligomerization in a ligand-inde-
pendent manner, after overexpression of tagged-p75NTR.
This result suggests, for the first time, the presence of a
specific self-association domain in the extracellular region
of p75NTR, but does not rule out the possibility of trimer-
ization. EVT901 also alters the ability of NGF to bind
p75NTR (Fig. 1). Moreover, EVT901 is unable to bind
to other TNFRs, confirming its specificity for p75NTR
(Fig. 1). Interestingly, CRD1-p75NTR, the shorter form
of p75NTR induced strong apoptosis and this is totally
abrogated by EVT901 (Fig. 1).
The short p75NTR variant (s-p75NTR) has also been
described and the complete absence of both p75NTR iso-
forms displays more severe phenotypes, but also leads to a
persistent increase in the number of cholinergic neurons in
the medial septum (von Schack et al., 2001; Naumann et
al., 2002; Roux and Barker, 2002). Given the significance
of cholinergic forebrain neurons in learning and memory
processes and their degeneration in Alzheimer’s disease, tar-
geting p75NTR seems to be essential with regard to the
modulation of the neuronal survival. S-p75NTR has been
also reported to bind to Rabies virus glycoprotein through
CRD1, and failed to bind neurotrophins (Langevin et al.,
2002).
Although p75NTR binds all neurotrophins with similar
nanomolar affinities, this receptor also interacts with pro-
neurotrophins (pro-NGF) and non-neurotrophin ligands
including the neurotoxic aggregated prion protein fragment
PrP106–126 and amyloid-b peptide. Increased expression of
these ligands promotes apoptosis in cultured neuronal cells
and animal models of neurodegenerative diseases through
activation of a p75NTR-dependent mechanism
(Hempstead, 2002). Our studies show that pro-NGF,
PrP106–126 or amyloid-b ligands trigger cell death in neuro-
blastoma cells and these pro-apoptotic effects are strongly
reduced by EVT901. Moreover, PrP106–126 and amyloid-b1–
40 induce strong apoptosis in HEK cells transfected with
full-length p75NTR or CRD1-p75NTR and are ineffective
on the CRD1-deleted form of the receptor. While the pre-
cise binding site of both neurotoxic peptides on p75NTR
has not been determined, our results suggest that their func-
tional epitopes may be different from that of these neuro-
trophins and are probably located at the level of CRD1.
Moreover, EVT901 could represent an innovative thera-
peutic approach for the treatment of many neurodegenera-
tive diseases where neurotoxic p75NTR ligands are
involved.
Many neuronal cells co-express Trk receptors and
p75NTR that could form a high affinity binding complex
with specificity in neurotrophin binding, and thus enhance
Trk signalling and subsequent neurotrophic effects (Roux
and Barker, 2002; Gentry et al., 2004; Underwood and
Coulson, 2008). EVT901 prevents ligand-independent
apoptosis on cells overexpressing p75NTR, but also
ligand-induced apoptosis in neuroblastoma cells expressing
both p75NTR and Trk receptors, mainly by interfering dir-
ectly with p75NTR oligomerization. Moreover, EVT901
stimulates neurite outgrowth, perhaps by enhancing the
interaction between p75NTR and TrkA receptors, as sup-
ported by enhanced TrkA phosphorylation. Therefore,
shifting the balance between p75NTR homo- to hetero-
oligomerization can positively modulate the TrkA signalling
pathway. Such modulation might be observed for other Trk
receptor signalling pathways, such as TrkB, thereby
increasing BDNF response, which could be beneficial in a
wide range of contexts, particularly Huntington’s disease.
The ability of EVT901 to inhibit p75NTR death signalling
and to enhance Trk, leading to both neuroprotective and
neurotrophic signalling in vitro, suggests that this com-
pound may be a disease-modifying drug candidate for the
treatment of neurodegenerative disorders and/or CNS
injury. Indeed, the beneficial effects of long-term treatment
after TBI shown in our FPI-TBI study could reflect
enhanced neural plasticity related to these neurotrophic ef-
fects. In addition, a recent study showed that proBDNF,
which interacts with p75NTR, suppresses neuronal remo-
delling and synaptic plasticity in cleavage-resistant
proBDNF knock-in mice (Yang et al., 2014). Although
we have not examined the potential involvement of
proBDNF in our TBI studies, we can speculate that
EVT901, through blocking p75NTR oligomerization, re-
duces proBDNF-induced p75NTR signalling in pathology
after TBI.P75NTR has been shown to be upregulated in
spinal cord injury, and to mediate apoptosis of oligo-
dendrocytes via proNGF (Beattie et al., 2002). Injury-
induced apoptosis of oligodendrocytes appears to be related
to cellular stress and inflammation (Sun et al., 2010).
Oligodendrocytes are also vulnerable to cell death in TBI
and exhibit caspase-3 activation (Lotocki et al., 2011).
Here, we expanded that recent finding by showing that a
CCI-TBI-induced rapid and transient expression of
p75NTR, proNGF, and caspase-3, and that p75NTR was
expressed in CC1-positive oligodendrocytes in the subcor-
tical white matter. Thus, EVT901 given during the week
after CCI-TBI preserved tissue integrity in the cortex and
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corpus callosum, spared CC1-positive oligodendrocytes in
the white matter and NeuN-positive cells in the cerebral
cortex, and positively impacted neurological function.
Using a different TBI model, we gave tests of memory
function to rats with FPI-TBI at 1 week following cessation
of a 23-day EVT901 or vehicle oral delivery regimen. FPI-
TBI produced severe memory deficits, indicated by the in-
ability to recognize novel objects and by a severe reduction
in freezing responses in the conditioned freezing paradigm.
Daily oral administration of EVT901, beginning 24 h post-
injury, significantly prevented the TBI-induced memory
deficit with full recovery at 1mg/kg/day. Interestingly, a
1-week treatment with EVT901 is sufficient to induce sig-
nificant memory recovery (data not shown).
Moreover, significant cell death was observed in the
hippocampus from 1–4 weeks after TBI and preceded emer-
gence of kainite-induced hypersensitivity (Routbort et al.,
1999; Covolan and Mello, 2000; Dechant and Barde,
2002). In addition to its effects on cell death, and neuro-
logical and cognitive outcomes, EVT901 also significantly
reduced TBI-induced hypersensitivity to pro-convulsive
agents (Fig. 8E). EVT901 treatment also considerably
reduced the per cent of rats exhibiting status epilepticus
(prolonged seizures induced by pro-convulsive agents), a
condition that induces marked alterations in neurotrophin
expression and persistent apoptosis in hippocampal, piri-
form, and entorhinal cortical neurons, mediated to a
large extent by activation of p75NTR signalling.
Regarding the effect of EVT901, we hypothesize that
blocking oligomerization of the p75NTR could prevent ac-
tivation of the receptor alone or through its interaction
with pro-neurotrophins, and might be related to the neuro-
protective effects observed with EVT901 during the first
week following trauma. Such effects may also prevent the
decrease of mossy fibres and thus the abnormal sprouting
process responsible for epileptogenesis.
The results of these two in vivo experiments suggest that
proNGF-induced cell death, mediated by p75NTR, occurs
in both neurons and oligodendrocytes after injury, and may
contribute to both sensorimotor and cognitive dysfunctions
after TBI. Post-injury microglial activation may lead to
astrogliosis, and both activated microglia and astrocytes
could be sources of proNGF leading to neuronal death
through p75NTR signalling (Domeniconi et al., 2007).
P75NTR could also mediate apoptotic neuronal cell death
during axonal degeneration (Harrington et al., 2004).
White matter injury, which leads to myelin debris frag-
ments binding to Nogo receptor, may involve p75NTR
signalling that contributes to axonal retraction and inhib-
ition of endogenous repair mechanisms (Hempstead, 2006;
Deinhardt et al., 2011). Indeed, recent reports have shown
that a different small molecule (LMA11-31A) that report-
edly affects p75NTR signalling by different mechanisms
can reduce cell death and enhance neurological function
following spinal cord injury (Tep et al., 2013), and can
reduce the deleterious effects of TBI on adult neurogenesis
(Shi et al., 2013). Unlike LMA11-31A, which inhibits the
binding of proNGF to p75NTR (Shi et al., 2013; Tep et al.,
2013), EVT901 blocks the interaction of p75NTR through
the CRD1 domain, resulting in prevention not only
proNGF, but also proNTs and oligomers (such as amyloid
peptide and prion peptide), that directly interact with
p75NTR. Due to these specific mechanisms of EVT901,
p75NTR could still interact with other co-receptor (such
as Trks) to promote neuroregenerative effects including
neurite outgrowth and neurogenesis.
Thus, EVT901, through direct interaction with p75NTR,
could modulate multiple intracellular signalling mechan-
isms, including reducing the initial neuronal damage and
subsequent axonal degeneration, and increase memory re-
covery. By activating neuronal repair, EVT901 may limit
the secondary injury due to progression of the lesion,
enhancing cognition and reducing the risk of hypersensitiv-
ity to pro-convulsive agents. Future studies are needed to
further elucidate whether inhibitors of p75NTR oligomer-
ization can promote neurogenesis and restore brain func-
tion after TBI. Recent reports from other laboratories
certainly seem to support this approach (Shi et al., 2013;
Sebastiani et al., 2015).
In summary, this study is the first report of a small mol-
ecule inhibitor of p75NTR pre-oligomerization, which dir-
ectly interacts with the CRD1 domain of this receptor,
strongly suggesting the presence of a PLAD domain. In
addition, these results highlight the potential benefit of tar-
geting the PLAD as a novel therapeutic approach to pre-
vent activation of TNF receptor superfamily members. The
novel mechanism of action of EVT901, its potency and
selectivity, its ability to simultaneously block p75NTR
death signalling and promote neuroprotective and neuro-
trophic effects make this a potentially useful compound
for the treatment of TBI and other neurodegenerative
diseases.
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